D'Souza, A., Mar, N., Parikh, R., Parikh, M., Arora, M., Hinton, S., . . . Quinn, D. (2024). 1993P A randomized, phase II trial to evaluate the safety and efficacy of eribulin mesylate in combination with atezolizumab compared to atezolizumab alone in subjects with locally advanced or metastatic transitional cell urothelial cancer where cisplatin-based treatment is not an option. Annals of oncology, 35, S1153. https://doi.org/10.1016/j.annonc.2024.08.2079
Chicago Style (17th ed.) CitationD'Souza, A.A, et al. "1993P A Randomized, Phase II Trial to Evaluate the Safety and Efficacy of Eribulin Mesylate in Combination with Atezolizumab Compared to Atezolizumab Alone in Subjects with Locally Advanced or Metastatic Transitional Cell Urothelial Cancer Where Cisplatin-based Treatment Is Not an Option." Annals of Oncology 35 (2024): S1153. https://doi.org/10.1016/j.annonc.2024.08.2079.
MLA (9th ed.) CitationD'Souza, A.A, et al. "1993P A Randomized, Phase II Trial to Evaluate the Safety and Efficacy of Eribulin Mesylate in Combination with Atezolizumab Compared to Atezolizumab Alone in Subjects with Locally Advanced or Metastatic Transitional Cell Urothelial Cancer Where Cisplatin-based Treatment Is Not an Option." Annals of Oncology, vol. 35, 2024, p. S1153, https://doi.org/10.1016/j.annonc.2024.08.2079.